Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04167228

Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria — CAVICOR  

Carbapenem-Resistant Enterobacteriaceae Infection Clinical Trial

Official title:
Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria

Clinical Trial Summary

Patients with infections caused by carbapenem-resistant enterobacteria treated with CAZ-AVI versus patients treated with BAT are compared. The BAT group includes fosfomycin, tigecycline, gentamicin, meropenem and colistin.

Clinical Trial Description

Carbapenem-resistant enterobacteria (CRE) are a public health problem. The morbidity and mortality of patients with invasive infections due to CRE are high. The best treatment is unknown, however, combination therapy with at least 2 active drugs is often recommended for high-risk patients, and monotherapy is probably not inferior to this in low-risk patients. Ceftazidime-avibactam is active against many CRE, and in some countries it has been prescribed under compassionate use programs for these infections; It has recently been approved by the FDA and the EMA for specific indications. Recent data suggest that ceftazidime-avibactam may be superior for the treatment of infections caused by sensitive CRE, rather than traditional regimens that often include colistin, usually combined with other drugs. However, these studies include a low number of patients and are subject to important biases. Additionally, the development of resistance to this drug during / after treatment has been described and is worrying. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04167228
Study type Observational
Source Maimónides Biomedical Research Institute of Córdoba
Contact
Status Completed
Phase
Start date October 1, 2019
Completion date May 5, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06051513 - Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection N/A
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Completed NCT04146337 - Fecal Microbiota Transplantation for Carbapenem-resistant Enterobacteriaceae Phase 2/Phase 3
Terminated NCT04876430 - Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems Phase 2/Phase 3
Enrolling by invitation NCT03924934 - Community-associated Highly-Resistant Enterobacterales
Recruiting NCT04583098 - The Effect of Fecal Microbiota Transplantation on the Decolonization of Multidrug-resistant Organisms
Recruiting NCT04535661 - Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children
Withdrawn NCT04785924 - Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections Phase 4
Terminated NCT05258851 - Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections Phase 3
Not yet recruiting NCT04746222 - Oral Capsule Faecal Microbiota Transplantation for CPE Decolonization Phase 2/Phase 3
Recruiting NCT04014413 - Safety and Efficacy of Fecal Microbiota Transplantation N/A
Recruiting NCT05871476 - Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated Animals N/A
Recruiting NCT05850871 - Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies N/A
Terminated NCT05210387 - Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections N/A
Not yet recruiting NCT06210542 - Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model
Not yet recruiting NCT05981430 - Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae N/A
Recruiting NCT06258551 - Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
Recruiting NCT05979545 - EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics Phase 4
Completed NCT04790565 - Fecal Microbiota Transplantation for Carbapenem Resistant Enterobacteriaceae Phase 2/Phase 3